Lopinavir/ritonavir trough concentrations with the tablet formulation in HIV-1-infected women during the third trimester of pregnancy

By Calza Leonardo   Manfredi Roberto   Trapani Filippo   Salvadori Caterina   Colangeli Vincenzo   Borderi Marco   Grossi Gabriele   Motta Roberto   Viale Pierluigi  

Scandinavian Journal of Infectious Diseases, Vol. 44, Iss. 5, 2012-05 ,pp. : 381-387

Informa Healthcare

Access to resources Recommend Favorite

Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: An open-label randomized controlled trial

By Andersson Lars-Magnus  

Scandinavian Journal of Infectious Diseases, Vol. 45, Iss. 7, 2013-07 ,pp. : 543-551

Informa Healthcare

Access to resources Recommend Favorite

Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in treatment-naïïve human immunodeficiency virus-1 patients in Sweden

By Thuresson Per-Olof   Heeg Bart   Lescrauwaet Benedicte   Sennfäält Karin   Alaeus Annette   Neubauer Aljoscha  

Scandinavian Journal of Infectious Diseases, Vol. 43, Iss. 4, 2011-04 ,pp. : 304-312

Informa Healthcare

Access to resources Recommend Favorite

Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir

By Calza Leonardo   Trapani Filippo   Salvadori Caterina   Magistrelli Eleonora   Manfredi Roberto   Colangeli Vincenzo   Di Bari Maria Assunta   Borderi Marco   Viale Pierluigi  

Scandinavian Journal of Infectious Diseases, Vol. 45, Iss. 2, 2013-02 ,pp. : 147-154

Informa Healthcare

Access to resources Recommend Favorite

Effects of NO‐Hybridization on the Immunomodulatory Properties of the HIV Protease Inhibitors Lopinavir and Ritonavir

By  

BASIC AND CLINICAL PHARMACOLOGY & TOXICOLOGY (ELECTRONIC), Vol. 117, Iss. 5, 2015-11 ,pp. : 306-315

John Wiley & Sons Inc

Access to resources Recommend Favorite